Researchers from Europe are teaming with the European Federation of Pharmaceutical Industries and Associations (EFPIA) to develop sensor technology that assesses the loss in mobility. Funded with €50 from the European Innovative Medicines Initiative 2 Joint Undertaking the project will be led by Newcastle University with support from Novartis.
With an eye on the senior population in Europe, the wearable technology will be utilized to detect gait issues, such as the prediction, detection and measurement of mobility loss in a range of therapeutic areas including obstructive pulmonary disease (COPD), Parkinson’s disease, multiple sclerosis, hip fracture recovery, proximal femoral fracture and congestive heart failure.
Ronenn Roubenoff, Global Translational Medicine Head, Musculoskeletal Disease at Novartis Institutes for Biomedical Research states “a key immediate impact will be on the design of clinical trials for novel treatment development, supporting better patient inclusion & stratification, more sensitive clinical outcomes, potential correlation of real-world patient reported outcome for evidence-based healthcare.
Recently Alphabet’s (Google) life science subsidiary Verily has developed a wearable called the Verily Study Watch that recently was approved by the FDA and Johnson and Johnson turned to Apple to leverage the Apple Watch for a major study. The European Innovative Medicines Initiative is a public-private partnership between the European Union and the pharmaceutical industry established in 2008 with an overall budget of €5.3 from 2008 until 2024.
Professor Lynn Rochester, Professor of Human Movement Science at Newcastle University is coordinating the MOBILISE-D consortium. She said: “Digital technology, including sensors worn on the body, have the potential to transform how we assess mobility and identify life-changing conditions. This will enable medical teams to intervene earlier and offer treatment to extend healthy life.”